Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 vaccination response in inflammatory rheumatic disease patients on immunomodulatory therapy
2021-000880-63Phase 4Completed
- Sponsor
- Skåne University Hospital
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tozinameran, ChAdOx1 nCoV-19 and elasomeran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Skåne University Hospital. Primary endpoint: Seroconversion rate after vaccination. Started Feb 2021; status: completed.
02
Drugs
tozinameranChAdOx1 nCoV-19elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000880-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000880-63.